[GlobeNewswire] – Alexion Pharmaceuticals, Inc., a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases, will visit the Nasdaq … Read more on this. Alexion Pharmaceuticals, Inc. (ALXN) , currently valued at $31.83B, began trading this morning at $138.91. Looking at the stock, its one day range is $138.91 to $142.81 with a trailing 52-week range being $130.51 to $208.88. Priced at 27.01x this year’s forecasted earnings, ALXN shares are relatively expensive compared to the industry’s -4.37x forward p/e ratio. In a review of the consensus earnings estimate this quarter, 21 sell-side analysts are looking at $1.13 per share, which would be $0.15 worse than the year-ago quarter and a $0.06 sequential decrease. What we find to be interesting is that the full-year EPS estimate of $5.19 is a $0.20 improvement when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $711.58 Million. If realized, that would be a 18.53% increase over the year-ago quarter. In terms of ratings, Citigroup Initiated ALXN at Buy (Feb 25, 2016). Previously, Credit Suisse Initiated ALXN at to Neutral. The average price target for ALXN shares by the analysts covering it is $203.00, which is 46.14% above where the stock opened. See more in (NASDAQ:ALXN) Similar Articles: Stock Update: Alexion Pharmaceuticals Inc (NASDAQ:ALXN) – Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2015 Results on Wednesday, February 3, 2016 Stock Update: Alexion Pharmaceuticals Inc (NASDAQ:ALXN) – Alexion Pharmaceuticals to Report Third Quarter 2015 Results on Thursday, October 29, 2015 Stock Update: Alexion Pharmaceuticals Inc (NASDAQ:ALXN) – Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) to Ring The Nasdaq Stock Market Closing Bell